Original articleRisk Factors for Loss of Visual Acuity among Patients with Uveitis Associated with Juvenile Idiopathic Arthritis: The Systemic Immunosuppressive Therapy for Eye Diseases Study
Section snippets
Study Population
The methods of the SITE cohort study have been described.18 For the purposes of this analysis, all patients from the SITE cohort who were diagnosed with JIA19 (or oligoarticular and rheumatoid factor–negative polyarticular juvenile rheumatoid arthritis before the publication of the newer criteria) and had an associated chronic uveitis were included. Enthesis-related acute or recurrent alternating anterior uveitis was not included. The patients reported in this article had been examined between
Characteristics of the Study Population at Presentation
The demographic and clinical characteristics of the study population are summarized in Table 1. A total of 327 patients with JIA-related uveitis were included in the study. The median age of diagnosis of JIA was 4.1 years, with a range from 4 months to 16.9 years. The follow-up duration ranged from 0 to 24 years, with a median follow up of 2.62 years among patients seen more than once. The majority of the participants were white (85.3%) and female (80.1%). At presentation, 269 patients (82%)
Discussion
In this large retrospective cohort of patients with JIA-associated uveitis, we assessed the incidence of VA loss and ocular complications and found that the time-updated presence of posterior synechiae, active anterior chamber inflammation, and intraocular surgery were associated with increased risk of incident vision loss across both VA thresholds (≤20/50 and ≤20/200) in a statistically significant fashion. These findings are consistent with the published literature.2, 4, 6, 7, 8, 9, 10, 11, 12
References (39)
- et al.
Visual loss associated with pediatric uveitis in English primary and referral centers
Am J Ophthalmol
(2003) - et al.
Course, complications, and outcome of juvenile arthritis-related uveitis
J AAPOS
(2008) - et al.
Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis
Ophthalmology
(1997) - et al.
Changing patterns in uveitis of childhood
Ophthalmology
(1996) Juvenile arthritis and uveitis
Surv Ophthalmol
(1990)- et al.
Analysis of pediatric uveitis cases at a tertiary referral center
Ophthalmology
(2005) - et al.
Mycophenolate mofetil therapy for inflammatory eye disease
Ophthalmology
(2005) - et al.
Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation
Ophthalmology
(2008) - et al.
Cyclosporine for ocular inflammatory diseases
Ophthalmology
(2010) - et al.
Cyclophosphamide for ocular inflammatory diseases
Ophthalmology
(2010)
Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment Trial
Ophthalmology
Prognosticators for visual outcome in sarcoid uveitis
Ophthalmology
Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel
Am J Ophthalmol
Prognostic factors in the uveitis of juvenile rheumatoid arthritis
Ophthalmology
American Academy of Pediatrics Section on Rheumatology and Section on Ophthalmology: guidelines for ophthalmologic examinations in children with juvenile rheumatoid arthritis
Pediatrics
Pathogenesis and clinical manifestations of juvenile rheumatoid arthritis
Korean J Pediatr
Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease
Arthritis Rheum
Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature
Graefes Arch Clin Exp Ophthalmol
American Academy of Pediatrics Section on Rheumatology, Section on OphthalmologyOphthalmologic examinations in children with juvenile rheumatoid arthritis
Pediatrics
Cited by (140)
Taiwan ocular inflammation society consensus recommendations for the management of juvenile idiopathic arthritis-associated uveitis
2024, Journal of the Formosan Medical AssociationDesign, optimization and pharmacokinetic evaluation of PLGA phosphatidylcholine hybrid nanoparticles of triamcinolone acetonide loaded in situ gel for topical ocular delivery
2023, International Journal of PharmaceuticsUveitis in children: Epidemiological, clinical and prognostic characteristics
2023, Journal Francais d'OphtalmologieMonitoring compliance to topical therapy in children and young people with uveitis
2024, Eye (Basingstoke)Establishing the Normative Data Set Necessary for Imaging-Based Childhood Uveitis Surveillance: A Cross-Sectional Study
2024, Investigative Ophthalmology and Visual ScienceComparison between intravitreous fluocinolone acetonide implant, ozurdex implant, and cyclosporine in treatment of noninfectious uveitic macular edema
2023, Journal of Medicinal and Chemical Sciences
Manuscript no. 2012-303.
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Supported primarily by Grant ey014943 from the National Eye Institute, National Institutes of Health, Bethesda, Maryland (Dr. Kempen). Additional support was provided by the Paul and Evanina Mackall Foundation, Philadelphia, Pennsylvania, and Research to Prevent Blindness Inc, New York, New York. Dr. Kempen is a Research to Prevent Blindness James S. Adams Special Scholar Award recipient. Dr. Thorne is a Research to Prevent Blindness Harrington Special Scholar Award recipient. Drs. Jabs and Rosenbaum are Research to Prevent Blindness Senior Scientific Investigator Award recipients. Dr. Levy-Clarke was previously and Dr. Nussenblatt continues to be supported by intramural funds of the National Eye Institute.